$LUMO
Lumos Pharma Inc Stock $lumo

$lumo Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-Q Financial Statement

#000112623416000316 Filed on November 08, 2016

Income Statement

Concept	2016 Q4	2016 Q3	2015 Q4
Revenue	$12.70M	$15.35M	$7.652M
YoY Change	66.01%	7.99%	-95.48%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.200M	$7.700M	$7.700M
YoY Change	-6.49%	4.05%	-7.23%
% of Gross Profit
Research & Development	$20.20M	$24.46M	$14.80M
YoY Change	36.49%	8.69%	24.37%
% of Gross Profit
Depreciation & Amortization	$600.0K	$300.0K	$500.0K
YoY Change	20.0%	-40.0%	66.67%
% of Gross Profit
Operating Expenses	$27.40M	$32.21M	$22.50M
YoY Change	21.78%	7.76%	11.39%
Operating Profit	-$13.97M	-$16.69M	-$14.83M
YoY Change	-5.77%	6.4%	-109.95%
Interest Expense	$100.0K	$5.000K	$0.00
YoY Change		-94.32%
% of Operating Profit
Other Income/Expense, Net	$100.0K	$19.00K	$0.00
YoY Change		-130.16%
Pretax Income	-$13.80M	-$16.85M	-$14.80M
YoY Change	-6.76%	7.0%	-109.93%
Income Tax	-$640.0K	-$1.308M	$6.700M
% Of Pretax Income
Net Earnings	-$13.51M	-$15.54M	-$21.57M
YoY Change	-37.4%	-2.3%	-117.98%
Net Earnings / Revenue	-106.32%	-101.27%	-281.94%
Basic Earnings Per Share	-$0.46	-$0.54	-$0.75
Diluted Earnings Per Share	-$0.46	-$0.54	-$0.75
COMMON SHARES
Basic Shares Outstanding	29.13M shares	28.98M shares	28.79M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q4	2016 Q3	2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$131.5M	$148.3M	$197.8M
YoY Change	-33.52%	-26.0%	-2.47%
Cash & Equivalents	$131.5M	$148.3M	$195.6M
Short-Term Investments	$0.00	$0.00	$2.200M
Other Short-Term Assets	$5.900M	$10.70M	$5.000M
YoY Change	18.0%	494.44%	-39.76%
Inventory
Prepaid Expenses	$5.921M	$10.69M	$4.954M
Receivables
Other Receivables	$24.53M
Total Short-Term Assets	$167.9M	$179.2M	$208.1M
YoY Change	-19.33%	-17.51%	-6.92%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.835M	$7.188M	$10.40M
YoY Change	-34.28%	-25.34%	36.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$6.835M	$7.188M	$10.40M
YoY Change	-34.28%	-25.34%	36.86%
TOTAL ASSETS
Total Short-Term Assets	$167.9M	$179.2M	$208.1M
Total Long-Term Assets	$6.835M	$7.188M	$10.40M
Total Assets	$174.7M	$186.3M	$218.5M
YoY Change	-20.04%	-17.84%	-5.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$22.88M	$2.367M	$3.661M
YoY Change	525.05%	58.43%	51.78%
Accrued Expenses	$14.31M	$37.26M	$8.761M
YoY Change	63.33%	356.89%	-6.47%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$200.0K	$200.0K	$558.0K
YoY Change	-64.16%	-64.16%	255.41%
Total Short-Term Liabilities	$37.91M	$40.65M	$14.84M
YoY Change	155.42%	262.42%	-40.69%
LONG-TERM LIABILITIES
Long-Term Debt	$300.0K	$300.0K	$368.0K
YoY Change	-18.48%	-26.65%	-60.89%
Other Long-Term Liabilities	$7.100M	$7.100M	$7.600M
YoY Change	-6.58%	-8.97%	-8.43%
Total Long-Term Liabilities	$7.376M	$7.422M	$7.928M
YoY Change	-6.96%	-9.4%	-14.42%
TOTAL LIABILITIES
Total Short-Term Liabilities	$37.91M	$40.65M	$14.84M
Total Long-Term Liabilities	$7.376M	$7.422M	$7.928M
Total Liabilities	$45.28M	$48.07M	$22.77M
YoY Change	98.88%	147.68%	-33.59%
SHAREHOLDERS EQUITY
Retained Earnings	-$165.5M	-$152.0M	-$80.35M
YoY Change	105.98%	158.6%	101.08%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$853.0K	$784.0K	$771.0K
YoY Change	10.64%	42.29%	247.3%
Treasury Stock Shares	30.05K shares	25.23K shares	24.03K shares
Shareholders Equity	$129.5M	$138.3M	$195.8M
YoY Change
Total Liabilities & Shareholders Equity	$174.7M	$186.3M	$218.5M
YoY Change	-20.04%	-17.84%	-5.48%

Cashflow Statement

Concept	2016 Q4	2016 Q3	2015 Q4
OPERATING ACTIVITIES
Net Income	-$13.51M	-$15.54M	-$21.57M
YoY Change	-37.4%	-2.3%	-117.98%
Depreciation, Depletion And Amortization	$600.0K	$300.0K	$500.0K
YoY Change	20.0%	-40.0%	66.67%
Cash From Operating Activities	-$17.00M	-$13.20M	-$8.400M
YoY Change	102.38%	88.57%	-106.43%
INVESTING ACTIVITIES
Capital Expenditures	-$100.0K	-$100.0K	-$500.0K
YoY Change	-80.0%	-92.31%	25.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$1.000M
YoY Change	-100.0%	-100.0%	-76.74%
Cash From Investing Activities	-$200.0K	-$100.0K	$500.0K
YoY Change	-140.0%	-66.67%	-87.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	400.0K	1.100M	6.400M
YoY Change	-93.75%	10.0%	33.33%
NET CHANGE
Cash From Operating Activities	-17.00M	-13.20M	-8.400M
Cash From Investing Activities	-200.0K	-100.0K	500.0K
Cash From Financing Activities	400.0K	1.100M	6.400M
Net Change In Cash	-16.80M	-12.20M	-1.500M
YoY Change	1020.0%	93.65%	-101.08%
FREE CASH FLOW
Cash From Operating Activities	-$17.00M	-$13.20M	-$8.400M
Capital Expenditures	-$100.0K	-$100.0K	-$500.0K
Free Cash Flow	-$16.90M	-$13.10M	-$7.900M
YoY Change	113.92%	129.82%	-106.03%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1022000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Other Assets Acquired1 NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1	231000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	195000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Period End Date DocumentPeriodEndDate	2016-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001126234
CY2016Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	29134623	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	NEWLINK GENETICS CORP
	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2014Q4	nlnk	Genentech Upfront Payments GenentechUpfrontPayments	150000000	USD
	nlnk	Generalandadministrativerestructuringexpense Generalandadministrativerestructuringexpense	500000	USD
	nlnk	Merck One Time Milestones MerckOneTimeMilestones	20000000	USD
CY2014Q4	nlnk	Merck Upfront Payments MerckUpfrontPayments	30000000	USD
	nlnk	Researchanddevelopmentrestructuringexpense Researchanddevelopmentrestructuringexpense	11800000	USD
CY2015Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	5388000	USD
CY2016Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	14995000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3661000	USD
CY2016Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2367000	USD
CY2015Q4	us-gaap	Accrued Fees And Other Revenue Receivable AccruedFeesAndOtherRevenueReceivable	4100000	USD
CY2016Q3	us-gaap	Accrued Fees And Other Revenue Receivable AccruedFeesAndOtherRevenueReceivable	14000000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8761000	USD
CY2016Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	37259000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6500000	USD
CY2016Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5200000	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	276610000	USD
CY2016Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	290772000	USD
	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	-640000	USD
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3300000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12400000	USD
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3900000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13100000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	3976000	USD
CY2015Q4	us-gaap	Assets Assets	218542000	USD
CY2016Q3	us-gaap	Assets Assets	186344000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	208142000	USD
CY2016Q3	us-gaap	Assets Current AssetsCurrent	179156000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	190404000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	197141000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5021000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	4808000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	195620000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	148276000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6737000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-47344000	USD
CY2015Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	2180000	USD
CY2016Q3	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	0	USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28838176	shares
CY2016Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29116879	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28814142	shares
CY2016Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29091652	shares
CY2015Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	288000	USD
CY2016Q3	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	291000	USD
CY2015Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	96000	USD
CY2016Q3	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	81000	USD
CY2015Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1153000	USD
CY2016Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1089000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	892000	USD
CY2016Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	693000	USD
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	407000	USD
CY2016Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1071000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1536000	USD
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.55
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.66
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.54
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.48
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	0	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	640000	USD
	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	397000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	397000	USD
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7384000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23007000	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7749000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26043000	USD
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-15746000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-18807000	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-16848000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-76670000	USD
CY2015Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	160000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1308000	USD
CY2015Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	0	USD
CY2016Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	5197000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1780000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	27204000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	8687000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-6056000	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	62000	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	79000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-12542000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-606000	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	11261000	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	9607000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-6565000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	5734000	USD
CY2015Q3	us-gaap	Interest Expense InterestExpense	88000	USD
	us-gaap	Interest Expense InterestExpense	98000	USD
CY2016Q3	us-gaap	Interest Expense InterestExpense	5000	USD
	us-gaap	Interest Expense InterestExpense	18000	USD
	us-gaap	Interest Paid InterestPaid	37000	USD
	us-gaap	Interest Paid InterestPaid	18000	USD
CY2015Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	25000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	68000	USD
CY2016Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	68000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	180000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	22768000	USD
CY2016Q3	us-gaap	Liabilities Liabilities	48067000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	218542000	USD
CY2016Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	186344000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14840000	USD
CY2016Q3	us-gaap	Liabilities Current LiabilitiesCurrent	40645000	USD
CY2015Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	939000	USD
CY2016Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	578000	USD
CY2015Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	7928000	USD
CY2016Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	7422000	USD
CY2016Q3	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	653000	USD
CY2015Q3	us-gaap	Licenses Revenue LicensesRevenue	844000	USD
	us-gaap	Licenses Revenue LicensesRevenue	34555000	USD
CY2016Q3	us-gaap	Licenses Revenue LicensesRevenue	888000	USD
	us-gaap	Licenses Revenue LicensesRevenue	3008000	USD
CY2015Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	368000	USD
CY2016Q3	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	333000	USD
CY2015Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	571000	USD
CY2016Q3	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	245000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	16745000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1478000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	5727000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	111000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-15906000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-18807000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-15540000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-15735000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-48933000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-71649000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Other Assets Acquired1 NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1	0	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	29892000	USD
	us-gaap	Operating Expenses OperatingExpenses	79626000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	32212000	USD
	us-gaap	Operating Expenses OperatingExpenses	99853000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-15683000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18777000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-16867000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-76788000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1100000	USD
CY2016Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	18300000	USD
CY2015Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	6000000	USD
CY2016Q3	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	6000000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	397000	USD
CY2016Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	44000	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	44000	USD
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-63000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-30000	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	19000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	118000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	341000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	13000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3450000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2069000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2016Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0.00	shares
CY2016Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0.00	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2016Q3	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2015Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4954000	USD
CY2016Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	10688000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	17230000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1686000	USD
	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	9177000	USD
	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	2180000	USD
	us-gaap	Profit Loss ProfitLoss	-18807000	USD
CY2016Q3	us-gaap	Profit Loss ProfitLoss	-15500000	USD
	us-gaap	Profit Loss ProfitLoss	-71600000	USD
	us-gaap	Profit Loss ProfitLoss	-71649000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10400000	USD
CY2016Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7188000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	144000	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22508000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	56619000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-80353000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24463000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	73810000	USD
	us-gaap	Restructuring Charges RestructuringCharges	12300000	USD
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-152002000	USD
CY2015Q3	us-gaap	Revenue From Grants RevenueFromGrants	13365000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	26294000	USD
CY2016Q3	us-gaap	Revenue From Grants RevenueFromGrants	14457000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	20057000	USD
CY2015Q3	us-gaap	Sales Revenue Net SalesRevenueNet	14209000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	60849000	USD
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	15345000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	23065000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	12394000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	13119000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	115566	shares
	us-gaap	Stock Issued During Period Shares Employee Stock Ownership Plan StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan	37888	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	240815	shares
	us-gaap	Stock Issued During Period Value Employee Stock Ownership Plan StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan	363000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	13119000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1323000	USD
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	13000	USD
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	195774000	USD
CY2016Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	138277000	USD
	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	4000000	USD
CY2015Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	859000	USD
CY2016Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	0	USD
CY2015Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	24034	shares
CY2016Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	25227	shares
	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	1193	shares
CY2015Q4	us-gaap	Treasury Stock Value TreasuryStockValue	771000	USD
CY2016Q3	us-gaap	Treasury Stock Value TreasuryStockValue	784000	USD
CY2015Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	3600000	USD
CY2016Q3	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	9700000	USD
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28734768	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28518503	shares
CY2016Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28983561	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28911042	shares
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">escription of Business</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 4, 1999, NewLink Genetics Corporation (NewLink) was incorporated as a Delaware corporation. NewLink was formed for the purpose of developing treatments for patients with cancer and other diseases. NewLink initiated operations in April 2000. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2005, NewLink created a partially owned subsidiary, BioProtection Systems Corporation (BPS). NewLink contributed certain licensing agreements and other intangible assets for BPS to create vaccines against potential biological terror threats. On January 7, 2011, NewLink acquired all of the minority interest in BPS by merging a newly formed subsidiary of NewLink with BPS, with BPS as the surviving corporation, resulting in NewLink owning all the outstanding capital stock of BPS.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2013, NewLink created a wholly-owned subsidiary, NewLink International (NI). NewLink plans to conduct all or a portion of its operations outside of the United States through NI. In 2014, NewLink created another wholly owned subsidiary, NewLink Global (NG), which was subsequently merged into NewLink during 2014.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NewLink and its subsidiaries (the Company) are devoting substantially all of their efforts toward research and development. The Company has never earned revenue from commercial sales of its drugs. The Company incurred a net loss of </font><font style="font-family:inherit;font-size:10pt;">$15.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$71.6 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September 30, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2016, the Company announced that its Phase 3 clinical trial IMPRESS (IMmunotherapy for Pancreatic RESectable cancer Study) of algenpantucel-L for patients with resected pancreatic cancer did not achieve its primary endpoint and the Company's management adopted a restructuring plan designed to better align the Company's workforce and operating costs to its revised pipeline development plans and operating needs. The restructuring plan included a reduction in the Company's workforce; the exit or reduction of certain leased facilities; and the renegotiation or termination of contracts with certain third parties. In connection with the restructuring plan, the Company also discontinued the development of its commercial manufacturing capabilities for algenpantucel-L, discontinued programs supporting the future commercialization of algenpantucel-L, and recorded an impairment charge to fixed assets. The Company has retained some internal manufacturing ability to support the development of clinical supplies for its ongoing clinical trials of the other HyperAcute Cellular Immunotherapy product candidates. Refer to Note 9 for more information.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> have been prepared assuming the Company will continue as a going concern. The Company successfully raised net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$37.6 million</font><font style="font-family:inherit;font-size:10pt;"> from its IPO, completed a follow-on offering of its common stock raising net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$49.0 million</font><font style="font-family:inherit;font-size:10pt;">, and raised an additional </font><font style="font-family:inherit;font-size:10pt;">$58.7 million</font><font style="font-family:inherit;font-size:10pt;"> in net proceeds from the at the market (ATM) offering. In connection with two license and collaboration agreements the Company entered into during 2014, the Company received a nonrefundable upfront cash payment of </font><font style="font-family:inherit;font-size:10pt;">$150.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Genentech Inc., a member of the Roche Group, or Genentech, in 2014, and a nonrefundable upfront cash payment of </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Merck, Sharpe and Dohme Corp., or Merck, in 2014, as well as a milestone payment of </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Merck in February 2015. The Company's cash and cash equivalents after these agreements and offerings are expected to be adequate to satisfy the Company's liquidity requirements through 2018. If available liquidity becomes insufficient to meet the Company’s operating obligations as they come due, the Company's plans include pursuing alternative funding arrangements and/or reducing expenditures as necessary to meet the Company’s cash requirements. However, there is no assurance that, if required, the Company will be able to raise additional capital or reduce discretionary spending to provide the required liquidity. Failure by the Company to successfully execute its plans or otherwise address its liquidity needs may have a material adverse effect on its business and financial position, and may materially affect the Company’s ability to continue as a going concern.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001126234-16-000316-index-headers.html	Edgar Link	pending
0001126234-16-000316-index.html	Edgar Link	pending
0001126234-16-000316.txt	Edgar Link	pending
0001126234-16-000316-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
idopipelinechartq32016a01.jpg	Edgar Link	pending
newlinklogorgbwtaga01a01a06.jpg	Edgar Link	pending
nlnk-20160930.xml	Edgar Link	completed
nlnk-20160930.xsd	Edgar Link	pending
nlnk-20160930x10q.htm	Edgar Link	pending
nlnk-20160930xex101.htm	Edgar Link	pending
nlnk-20160930xex311.htm	Edgar Link	pending
nlnk-20160930xex312.htm	Edgar Link	pending
nlnk-20160930xex321.htm	Edgar Link	pending
nlnk-20160930_cal.xml	Edgar Link	unprocessable
nlnk-20160930_def.xml	Edgar Link	unprocessable
nlnk-20160930_lab.xml	Edgar Link	unprocessable
nlnk-20160930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LUMO
Lumos Pharma Inc Stock $lumo

2016 Q4 Form 10-Q Financial Statement

#000112623416000316 Filed on November 08, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUMO Lumos Pharma Inc Stock $lumo

2016 Q4 Form 10-Q Financial Statement

#000112623416000316 Filed on November 08, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUMO
Lumos Pharma Inc Stock $lumo